Pure red-cell aplasia and epoetin therapy. - Wikidata - wikimedia - TriplyDB

Pure red-cell aplasia and epoetin therapy.

Pure red-cell aplasia and epoetin therapy.

http://www.wikidata.org/entity/Q50785055

about

Subcutaneous versus intravenous erythropoietin for long-term dialysis patients Subcutaneous versus intravenous erythropoietin for long-term dialysis patients Erythropoietin or Darbepoetin for patients with cancer Anaemia in systemic lupus erythematosus: from pathophysiology to clinical assessment Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project Therapeutic issues in HIV/HCV-coinfected patients What do oncologists need to know about biosimilar products?Two mechanistic pathways for thienopyridine-associated thrombotic thrombocytopenic purpura: a report from the SERF-TTP Research Group and the RADAR Project.Drug-induced hematologic syndromes Pharmacotherapy of end-stage renal disease.Generic and therapeutic substitutions in the UK: are they a good thing?Improved drug-like properties of therapeutic proteins by directed evolution.Biosimilars: Implications for health-system pharmacists.Biosimilars 101: considerations for U.S. oncologists in clinical practice Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS).Regulatory and clinical considerations for biosimilar oncology drugs Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project Two different dosing regimens of human recombinant erythropoietin beta during preoperative autologous blood donation in patients having hip arthroplasty.Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration.New avenues of exploration for erythropoietin.Association of Erythropoietin Dose and Route of Administration with Clinical Outcomes for Patients on Hemodialysis in the United States Erythropoietin: an update on the therapeutic use in newborn infants and children.Acquired red cell aplasia in association with the use of recombinant erythropoietin in chronic renal failure.The role of rHuEpo in low-risk myelodysplastic syndrome patients.The development of erythropoietic agents in oncology.Epoetin alfa: basic biology and clinical utility in cancer patients.Taste and/or Odour Disturbances in Pediatric Patients Undergoing IV Flush with Normal Saline Administered by Prefilled Syringe.Long-term and stable correction of uremic anemia by intramuscular injection of plasmids containing hypoxia-regulated system of erythropoietin expression.Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye's syndrome. a report from the Southern Network on Adverse Reactions (SONAR).Definition and management of anemia in patients infected with hepatitis C virus.Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review Biochemistry, physiology, and complications of blood doping: facts and speculation.Current and future options for the treatment of chemotherapy-induced anaemia.Recombinant human epoetin beta in the treatment of renal anemia.Results from the first decade of research conducted by the Research on Adverse Drug Events and Reports (RADAR) project.Internal medicine, renal anaemia, and erythropoiesis-stimulating agents (ESAS).Treatment of Parkinson's disease with trophic factors.Epoetin-associated pure red cell aplasia: past, present, and future considerations Immunoglobulin G1 and immunoglobulin G4 antibodies in multiple sclerosis patients treated with IFNβ interact with the endogenous cytokine and activate complement.

P2860

Q24187032-0182962A-6801-4DA0-A203-34F8F067863F Q24200417-84B2FE47-3026-4976-B299-58EFF7A13CFB Q24245464-2ECF177A-A9AE-41F0-AD40-390107DD4939 Q24675466-F3D5AA57-35E4-4850-B31E-180C62690FE4 Q24814257-E7654963-A0E3-4F08-A557-C79E68B8CC88 Q27026618-1BC87D14-4C06-4375-B923-BACE27A8288E Q27481053-AE3EF7B5-3415-4951-9B2A-7F994C062088 Q28071687-EB2247DF-2626-4376-A985-68449630ED3E Q33376683-4ABC9841-2796-49B9-B2F6-2FAFA006B6D1 Q33387312-0DD0E462-F5C0-44AF-A7B3-C1A6B65184A2 Q33531889-F46FD4E0-6450-4278-A71C-8C0F041BC3DF Q34174851-67270160-594B-49B4-A5F0-9E389BE9AA21 Q34297201-AB6D8F82-D1FD-4FEE-80A3-4C5B36E10925 Q34372394-66267559-B35C-495F-B937-2A63B1C214D6 Q35000438-D8B76078-8FE5-49A0-B0BA-34A362F43FE5 Q35119023-0B791AAD-8D3C-4D31-B5C4-0F2AF182DB97 Q35505833-550FCD42-9F78-40B8-A8E0-E0A547A104E6 Q35847694-56FAB5A3-9664-4F65-99D1-088048D2B1A9 Q35851261-A8B6A166-0381-4386-BB03-75B2D636FB40 Q35967897-72D07978-2F96-4C9C-9DAA-FE081E373F74 Q35999785-B38EFB01-E947-46F9-8E97-9D26323F89DD Q36123609-561757FF-79B0-418E-8B95-E2C59C572D84 Q36150771-A8C5229C-1B0A-48FC-9522-0A89BA29E168 Q36194596-1803EBD2-9A35-4413-A02A-7A049D6DE558 Q36194667-B5E8622A-333B-447B-AB91-177C50F965BC Q36219651-543E4773-5AE9-409B-8B66-592F2B73DC6C Q36334861-5DA5B82C-3D8E-4BBC-8236-E4AEE3FBE348 Q36337606-BF8B54FB-BED4-4C3E-B47C-2D7709842929 Q36431079-0C8A2EFD-21F2-4158-B45B-7DA4B48AD9FF Q36431597-8F404C2B-AFA6-4150-AACD-2C975E90E163 Q36455842-38AC6EFD-DAC1-4DB2-AF76-005CDD0C055C Q36467377-A2A1538B-7A7D-413B-99F6-ADD7782C211A Q36504354-C4AC2197-E15B-4642-A498-9AF252DEC248 Q36568736-D46A5DF9-39E5-4A47-A834-C845BF0BAC29 Q36661294-FBD36A63-861F-4725-B1C5-7E63AF8719EA Q36920523-68424C64-B9CF-490E-B616-DA9841B7714B Q37113720-10F44534-7D65-4FE4-8DD8-7DCEACA07CA1 Q37131259-A050BDC5-E6A7-44EE-ADA5-45940B2E8039 Q37164738-3C98C0A1-4477-432A-B865-ED03F66DCCF6 Q37189729-2879E7FC-04C8-4A0F-BC03-5773D3B644B3

P2860

Pure red-cell aplasia and epoetin therapy.

http://www.wikidata.org/entity/Q50785055

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh-hant

name

Pure red-cell aplasia and epoetin therapy.

@en

Pure red-cell aplasia and epoetin therapy.

@nl

type

label

Pure red-cell aplasia and epoetin therapy.

@en

Pure red-cell aplasia and epoetin therapy.

@nl

prefLabel

Pure red-cell aplasia and epoetin therapy.

@en

Pure red-cell aplasia and epoetin therapy.

@nl

P1433

Q50785055-F0C3A8B9-3892-4CEB-B254-DFC74174DB0A

P1476

Q50785055-627C6C6A-79A6-47FF-AF7D-BA69F9CC7CA4

P2093

Q50785055-1B845606-28AE-4B71-8258-0720DF3ED36B

Q50785055-1C15A75D-FFB6-4FDD-9519-434BEE171E68

Q50785055-22527FA7-F8B9-4E41-AE25-8233D9E6BAC0

Q50785055-3071F32C-2E04-4C44-8D41-28E3B622D2EF

Q50785055-3C0457ED-9DD9-4E9F-9F88-60C2D3F1760A

Q50785055-58CEC60C-0F07-4071-B815-C70121F256E0

Q50785055-6732E2A7-0F09-4D22-B821-3A43E0E266A4

Q50785055-8013A17B-0A24-49C9-8963-3683A089B76D

Q50785055-8995DA22-83C3-4EA6-8F56-B02652488305

Q50785055-8F631AC7-3084-420D-9CCA-59D8B05DF95C

P304

Q50785055-9236B4FB-D644-4A49-92FD-4C05FAD1C875

P31

Q50785055-345A6F30-3366-46BD-88B0-4BE4CBEC2CBF

P356

Q50785055-B007D2CE-C17C-4620-91FF-CBBD98507FAB

P407

Q50785055-48A842A3-DAE2-4653-9D52-493E7303FD49

P433

Q50785055-23752C16-1B98-4F79-99B9-EBA5B7613266

P478

Q50785055-B572E4F4-8D73-4336-8D69-27CA120F194A

P50

Q50785055-0B88E40C-DB4F-4A52-9031-4CF1DEE8A233

Q50785055-AE483703-0D83-4D0A-928C-AD9B25ADBC3A

Q50785055-BC69CAE4-4BAF-4544-A1FA-981D69CACCF6

P577

Q50785055-1C48FD23-DAB0-41D8-8C41-055CC8B53E82

P5875

Q50785055-D120F5B4-F571-4DBB-924E-981F4E8499A7

P698

Q50785055-77EE28B9-6649-4532-BCBF-002DE0798D69

P356

P1433

The New England Journal of Medicine

P1476

Pure red-cell aplasia and epoetin therapy.

@en

P2093

Allen R Nissenson

http://www.w3.org/2001/XMLSchema#string

Benjamin Kim

http://www.w3.org/2001/XMLSchema#string

Charles L Bennett

http://www.w3.org/2001/XMLSchema#string

Dennis W Raisch

http://www.w3.org/2001/XMLSchema#string

E Allison Lyons

http://www.w3.org/2001/XMLSchema#string

Francesco Locatelli

http://www.w3.org/2001/XMLSchema#string

Glen T Schumock

http://www.w3.org/2001/XMLSchema#string

Jerôme Rossert

http://www.w3.org/2001/XMLSchema#string

June M McKoy

http://www.w3.org/2001/XMLSchema#string

Nicole Casadevall

http://www.w3.org/2001/XMLSchema#string

P304

1403-1408

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA040528

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

351

http://www.w3.org/2001/XMLSchema#string

P50

Steven M. Belknap

Martin S Tallman

P577

2004-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8256827

http://www.w3.org/2001/XMLSchema#string

P698

15459301

http://www.w3.org/2001/XMLSchema#string